Research programme: interleukin 2 therapies - Slate Bio
Latest Information Update: 05 Feb 2021
At a glance
- Originator Slate Bio
- Class Interleukins
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified